Forcyte Biotechnologies is advancing Mechanomedicine

We built the first and only platform for the discovery of small molecule drugs that control mechanical force generation in individual human cells (or cellular ensembles), as a new but exceedingly logical strategy against some of the biggest mechanodiseases in the world.

Enabling library-scale screening with force as a functional endpoint

Forcyte’s proprietary technology (“FLECS”) enables visualization and quantification of mechanical forces generated by ~millions of primary human cells, simultaneously. The fully automated high-throughput screening system discovers small molecules that modulate this cellular mechanical output, based on the shape changes of adhesive / fluorescent micropatterns, cast in vast arrays on across elastomeric films. The platform integrates proprietary technologies in material science, microtechnology, image analysis, and cellular biology to create the first standardized and automation-able disease model of mechanical cell force generation.

Engaged in research and translation phases across key mechanical disease areas

Forcyte is developing an internal pipeline across multiple therapeutic areas (*Mechanical Diseases) with high unmet needs. Current programs are in Preterm Labor (suppressing early spontaneous uterine contractions), Asthma (bronchodilation through relaxation of airway smooth muscle), Hypertension (vasodilation through relaxation of arterial smooth muscle), Liver Fibrosis (inhibition of TGFbeta-driven transdifferentiation of hepatic stellate cells using enhanced contraction as an indicator of fibrogenesis) and Spastic Bladder and Incontinence (regulating contraction of bladder smooth muscle).

Forcyte’s FLECS Mechanomedicine Discovery platform is built to generate previously inaccessible functional cell data to be used for launching new programs in partnerships with Pharma. The power of Forcyte’s unique and logical approach has been harnessed by Pharma users in their own projects as well as by numerous translation researchers globally. The technology was further validated by granted and pending patents, 6 peer reviewed publications and a dozen unique research applications.

Are you a researcher looking to buy FLECS assay well-plate products? Click here.